Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer

BACKGROUND: Single-agent pembrolizumab treatment of hormone receptor-positive metastatic breast cancer (MBC) has demonstrated modest clinical responses. Little is known about potential biomarkers or mechanisms of response to immune checkpoint inhibitors (ICIs) in patients with HR+ MBC. The present s...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Immunother Cancer
Auteurs principaux: Egelston, Colt, Guo, Weihua, Yost, Susan, Lee, Jin Sun, Rose, David, Avalos, Christian, Ye, Jian, Frankel, Paul, Schmolze, Daniel, Waisman, James, Lee, Peter, Yuan, Yuan
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2021
Sujets:
Immunotherapy Biomarkers
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7993344/
https://ncbi.nlm.nih.gov/pubmed/33757987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-002084
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires